Acadia Pharmaceuticals P/E Ratio

Acadia Pharmaceuticals (ACAD) currently reports a P/E ratio of 11.6. That is below the Healthcare sector average of 27.42. Use the charts on this page to explore Acadia Pharmaceuticals's P/E ratio history and peer comparisons.

Acadia Pharmaceuticals's P/E ratio of 11.6 is lower than the Healthcare sector average of 27.42. That is roughly 57.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Acadia Pharmaceuticals's market price to a fundamental measure such as earnings, sales, or book value. At 11.6, ACAD can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of 11.6, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 27.42. From there, open related valuation or income-statement pages for Acadia Pharmaceuticals, and consider following ACAD for alerts when major investors trade the stock.

Acadia Pharmaceuticals is classified in the Healthcare sector. On P/E ratio, it currently shows 11.6 versus a sector average near 27.42. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ACAD with unrelated industries.